Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients
- PMID: 33434667
- DOI: 10.1016/j.ijid.2021.01.011
Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients
Abstract
Background: Worldwide, seasonal influenza causes significant mortality and poses a significant economic burden. Oseltamivir is an effective treatment, but benefits beyond immediate hospitalization are unknown.
Methods: This retrospective multicenter study included adult hospitalized influenza patients from two major teaching hospitals in Australia. Patients who received Oseltamivir <48 h of admission (prompt-treatment group) were compared with those who either did not receive treatment or if treatment was delayed by >48 h (delayed/no-treatment group). Propensity-score matching was used to balance confounders between two groups. Primary outcomes included 30-day readmissions, 30-day mortality, composite-outcome (30-day mortality and readmissions), in-hospital mortality, and hospital length of stay (LOS).
Results: Between January 2016-March 2020, 1828 adult patients mean (SD) age 66.4 (20.1), 52.9% females, were hospitalized with influenza. Four hundred and forty-eight (24.5%) received prompt-treatment with Oseltamivir, while 1380 (75.5%) patients were in the delayed/no-treatment group. The median (IQR) time from onset of symptoms to the administration of Oseltamivir was three (1-5) days. The propensity-score model included 245 matched patients in each group (standardized mean difference of <10%). Both 30-day readmissions and the composite-outcome were, respectively, 5.7% (P = 0.03) and 6.5% (P = 0.02) lower in patients who received prompt-treatment with Oseltamivir when compared to the delayed/no-treatment group. LOS showed a significant reduction, and in-hospital mortality showed a trend towards improvement among patients who received prompt-treatment when compared to the other group.
Conclusions: Early administration of Oseltamivir was associated with a reduction in 30-days readmissions and composite-outcome of 30-day readmissions and mortality in adult hospitalized influenza patients when compared to delayed/no-treatment.
Keywords: Influenza; Mortality; Oseltamivir; Readmissions.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020.JAMA Pediatr. 2022 Nov 1;176(11):e223261. doi: 10.1001/jamapediatrics.2022.3261. Epub 2022 Nov 7. JAMA Pediatr. 2022. PMID: 36121673 Free PMC article.
-
Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study.Pediatr Infect Dis J. 2011 Nov;30(11):962-6. doi: 10.1097/INF.0b013e318232ede9. Pediatr Infect Dis J. 2011. PMID: 21997661 Free PMC article.
-
Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection.Int J Antimicrob Agents. 2020 Nov;56(5):106155. doi: 10.1016/j.ijantimicag.2020.106155. Epub 2020 Sep 6. Int J Antimicrob Agents. 2020. PMID: 32898685
-
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246. doi: 10.3310/hta13110. Health Technol Assess. 2009. PMID: 19215705 Review.
-
Managing seasonal influenza: oseltamivir treatment policy in indonesia?Acta Med Indones. 2014 Jan;46(1):58-65. Acta Med Indones. 2014. PMID: 24760811 Review.
Cited by
-
K-medoids clustering of hospital admission characteristics to classify severity of influenza virus infection.Influenza Other Respir Viruses. 2023 Mar 7;17(3):e13120. doi: 10.1111/irv.13120. eCollection 2023 Mar. Influenza Other Respir Viruses. 2023. PMID: 36909298 Free PMC article.
-
Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea.Epidemiol Health. 2022;44:e2022034. doi: 10.4178/epih.e2022034. Epub 2022 Mar 12. Epidemiol Health. 2022. PMID: 35381167 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
